Blood Advances
Overview
Blood Advances is a peer-reviewed medical journal that focuses on the latest advancements in hematology. It publishes cutting-edge research and clinical studies related to blood disorders, transfusion medicine, and hematologic malignancies. With a multidisciplinary approach, the journal provides valuable insights into the diagnosis, treatment, and management of various blood-related conditions, making it an essential resource for hematologists, oncologists, and researchers in the field.
Details
Details
Abbr.
Blood Adv
Start
2016
End
Continuing
Frequency
Semimonthly
p-ISSN
2473-9529
e-ISSN
2473-9537
Country
United States
Language
English
Specialty
Hematology
Metrics
Metrics
h-index / Ranks: 4009
85
SJR / Ranks: 575
3065
CiteScore / Ranks: 1055
11.50
JIF / Ranks: 763
7.5
Recent Articles
11.
Karkoska K, Jacob S, McGann P
Blood Adv
. 2025 Mar;
PMID: 40085957
Crizanlizumab and voxelotor were several of the first drugs to receive FDA approval for sickle cell disease (SCD) since the approval of hydroxyurea in 1998. Although initially exciting, additional data...
12.
Hu B, Reagan P, Sehn L, Sharman J, Hertzberg M, Zhang H, et al.
Blood Adv
. 2025 Mar;
PMID: 40085955
In the phase 3 POLARIX study, polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) improved progression-free survival (PFS) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in patients with...
13.
Shah M, Hung MBBS FRACP FRCPA K, Baranwal A, Kutyna M, Al-Kali A, Toop C, et al.
Blood Adv
. 2025 Mar;
PMID: 40085954
This retrospective analysis aimed to provide evidence-based risk-stratification of TP53-mutated (TP53mut) myeloid neoplasms (MN). Of 580 MN harboring TP53mut with variant allele frequency (VAF) ≥2%, 219 (37.8%), 194 (33.4%), 92...
14.
Durrani J, Chen L, Shalhoub R, Baez V, Glass J, Cha N, et al.
Blood Adv
. 2025 Mar;
PMID: 40085951
Immune aplastic anemia (iAA) frequently results in transfusion dependence for platelets and packed red blood cells (PRBC), increasing the risk for complications. The most common immune mediated cause for platelet...
15.
Azhwar R, Richter C, Griffin M, Emly S, Yaman M, Arruda V, et al.
Blood Adv
. 2025 Mar;
PMID: 40085950
Deficiencies in coagulation factor VIII (FVIII, F8) result in the bleeding disorder hemophilia A. An emerging novel therapeutic strategy for bleeding disorders is to enhance hemostasis by limiting natural anticoagulants,...
16.
Kim E, Malespini J, Lei M, Han S, Minsky C, Branagan A, et al.
Blood Adv
. 2025 Mar;
PMID: 40085948
Cast nephropathy is the most common cause of acute kidney injury (AKI) in patients with multiple myeloma (MM). A prompt reversal of renal injury is paramount for improving clinical outcomes....
17.
Naggayi S, Kalibbala D, Mboizi V, Ssenkusu J, Jin Z, Rosano C, et al.
Blood Adv
. 2025 Mar;
PMID: 40085947
Children with sickle cell anemia (SCA) frequently develop progressive neurocognitive impairment. We aimed to determine effects of hydroxyurea therapy on neurocognitive function in Ugandan children with SCA by comparing levels...
18.
Siciliano A, DAlessandro A, Matte A, Bisello G, Bertoldi M, Dzieciatkowska M, et al.
Blood Adv
. 2025 Mar;
PMID: 40085946
beta-thalassemia (beta-thal) is a worldwide hereditary red cell disorder characterized by severe chronic anemia. Recently, the pyruvate kinase (PK) activator mitapivat has been shown to improve anemia and ineffective erythropoiesis...
19.
Dupuy A, Liu X, Kong Y, Qi M, Perdomo J, Fenwick J, et al.
Blood Adv
. 2025 Mar;
PMID: 40085945
Vaccine-induced immune thrombotic thrombocytopenia (VITT) is a rare, but serious, complication of the ChAdOx1 nCOV-19 vaccine. In Australia, the diagnosis of VITT required the detection of antibodies against platelet factor...
20.